



President's Activity Report 2018-2021

Nicolaus Kröger – March 2022



Hello!



**In the next slides, you will read
the summary of my four-year presidency,
thanks to your strong and continuous support.**


My vision four years ago was to:

- Accelerate the process of professionalisation in our society by restructuring the organisation
- Improving quality standards including monitoring and assuring EBMT follows EU regulations within the different EBMT locations
- Realise In-house Annual Meeting and Working Party events
- Consolidate the Education & Events Unit as event organizing agency. Implement a "Scientific Director"
- Continue to establish a user-friendly, comprehensive, flexible and adaptive system of data collection and retrieval
- Implementation of a Cell Therapy Registry and increase focus on cellular therapies and increase the number of Post Authorization Marketing Studies (PASS) and Non-Interventional (NIS) Studies
- Increasing personal qualification of physicians, nurses, data managers and health care providers, who are involved in stem cell transplantation by providing structured web-based and printed educational tools, curricula and ultimately also personal certifications
- Increase Scientific Exchange by organizing smaller (midsize) scientific meetings/workshops in collaboration with other organisations
- Educate the next "Leadership Generation" for stem cell transplantation
- Increase focus on patient and family orientation
- increasing the number of JACIE Accreditation of Centers in Europe and implement the stepped process for centers in LMICs (low and middle-income countries)
- Increasing visibility especially on the public policy forum to influence decision making at EU level for improving regulatory hurdles
- Elevating the EBMT "brand" update Mission, Vision, Values and EBMT logo
- Enlarge Sponsors' support and reach the Cell Therapy sponsors by developing new partnership strategies

Current and past board Members during the last 4 years



Our Community, the membership growth



Our Sponsors 2018-2021



Collaborative relationship with sister societies

EBMT intensified the **collaborative relationship with our sister societies**, with the main aim to build a network of experts and/or centers (Doctors, Nurses and Data Managers) to exchange knowledge and experience through high quality science projects and/or educational events addressing important issues in HSCT.



Restructuring the organigram


The managerial infrastructure has been restructured since 2019. Currently, the EBMT is organised it in **four core departments**:

1. Clinical Research
2. Registry
3. Education & Events
4. Advocacy & Quality of Care

There are also two transversal departments: Support and Sales.

Furthermore, in 2020, we recruited a **Medical Officer** (Isabel Sánchez-Ortega) to support all medical aspects within the organization.

34 staff members joined the EBMT from 2018 to 2021



EBMT Departments Directors

Medical Officer

Isabel Sánchez-Ortega
(2020 to present)



Executive Director

Andreu Gusi
(2010 to present)



Registry Department



Carmen Ruiz
(1999 to 2019)



Debra Gordon
(2018 to 2020)



Bas Middelkoop
(2020 to present)

Clinical Research Department



Marianne Mol
(2016 to present)

Education Department



Alanna Mueller
(2019 to 2021)



Noemi San Emeterio
(2021 to present)

Advocacy & Quality of care Department




Eoin McGrath
(2003 to 2022)



Tuula Rintala
(2022 to present)

Financial situation

EBMT Finances in Million €






Science



Scientific Output

High scientific productivity



Scientific Output

High scientific productivity



Safety and Quality at EBMT

EBMT is strongly committed to protecting the privacy of personal data that we maintain about patients, donors, members and employees.

- In the context of the Good Clinical Practice (GCP) and the General Data Protection Regulation (GDPR), the EBMT implemented a safety and quality systems upgrade in the Clinical Trials Office in Leiden and recruited a data protection and quality management coordinator in the Executive Office in Barcelona (2018).
- Increasing regulatory requirements and proper implementation of the GDPR has led to some delay in starting the CAR T-cell PAS studies resulting in new and more efficient department structures including a Joint Controllershship Agreement (JCA) between the organisation and its members (2021).

Registry - Upgrade Project

- The Registry office worked with Elsevier, the chosen supplier for the **new Registry System** (MACRO) (2018-2021)
- The migration of the ProMISe database to MACRO was not concluded as expected. It was too complex and unexpected hurdles on both sides prevented a go live. The EBMT Board came to the conclusion in alignment with Elsevier to part ways and end the contract.
- The Registry had to make a switch in approach regarding the Registry Upgrade project. The Registry office ran the Flash project to identify a new vendor for the future Registry platform.

Registry - Qualification Opinion

- In the summer of 2018, EMA issued the first two marketing authorisations for CAR T-cells medicines in the European Union. Among the conditions imposed by EMA is the utilisation of a patient registry as part of the risk management measures for these two new medicines in order to monitor long-term safety and efficacy.
- The EBMT engaged with the European Medicines Agency (EMA) regarding the EBMT Registry and this led to the publication by EMA in July 2018 of the **draft positive qualification opinion on the cellular therapy module of the EBMT Registry for public consultation**. The publication of the draft EMA opinion drove a sharp increase in interest among pharmaceutical companies in collaborating with EBMT to collect long-term safety data for Chimeric Antigen Receptor (CAR) T-cell therapy and Immune Effector Cells (July 2018).
- EBMT receives a **regulatory qualification** from the European Medicine Agency (EMA) on the use of its patient registry to support novel CAR T-cell therapies (1 March 2019).



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH


Registry - Data collection on cellular therapy

- A new **Cellular and Gene Therapy form** was implemented after harmonisation with CIBMTR; it includes the requirements of the EMA and the needs of the pharmaceutical industry for the upcoming post-authorisation safety studies (PASS) (2018).
- EBMT decided to use Castor EDC (electronic data capture tool) as an alternative solution to ProMISe for the data collection on cellular therapy (2021).

Registry - Registrations for Cell Therapy

- Since 2019, the Registry has actively encouraged centres to report on all cases involved in the treatment of patients using a CAR-T product whether commercial or investigational.


Number of CAR T-cell treated patients registered* in the EBMT Registry



Source: EBMT Registry, December 2021

*Patients identified and marked with a CAR T-cell treatment, having at least minimal data on the diagnosis and treatment.

Countries reporting CAR T-cell treated patients to the EBMT Registry




Source: EBMT Registry, December 2021

Registry - Collaboration with Pharmas

- In 2020, the EBMT announced new collaborations with pharmaceutical companies to study the long-term outcomes of patients treated with CAR T therapies.
 - Novartis Pharmaceuticals
 - Kite, a Gilead Company
 - Bristol Myers Squibb (Celgene)



COVID-19 and EBMT



- In 2020, due to fast spreading of SARS-CoV-2 a panel of experts of EBMT (IDWP) started to produce **recommendations and guidelines** for transplant units, recipients, and donors of hematopoietic cells. Since its start in 2020, these guidelines have been updated when new information is obtained about COVID-19 epidemiology and clinical outcome.
- The Infectious Diseases Working Party produced **information on COVID-19 vaccines**, also published on the EBMT website.
- Creation of the EBMT **COVID-19 Task Force** to support patients and the EBMT Community throughout the COVID-19 pandemic.
- 9 COVID-focus **webinars** for physicians and nurses, were organised with other sister societies



Education

In-person Annual Meetings

- **44th Annual Meeting** of the EBMT in Lisbon. 18 - 21 March 2018
5,261 delegates from 87 countries.
- **45th Annual Meeting** of the EBMT in Frankfurt. 24-27 March 2019
5,640 participants from 94 countries.
 - Inclusion of the Patient, Family and Donor Day into the Congress
 - 1st Transplant Coordinator Day



Virtual Annual Meetings

- 46th Annual Meeting** of the EBMT. Initially planned to be held in Madrid, was first postponed and then finally performed as a completely **virtual meeting**. The Education and Events Department had to organise and re-organise the Annual Meeting a total of three times.

29 August – 1 September, 2020

6,783 registered attendees from 89 countries.

- **47th Annual Meeting** of the EBMT. Virtual.


14 - 17 March, 2021

5,253 registered attendees from 83 countries.




Annual Meeting in figures

EBMT Annual Meeting attendance




EBMT Annual Meeting benefit in million €



Specialised **educational events** offering in-depth content for all of the sub-specialities within BMT and Cellular Therapy.

- **1st European CAR T Cell Meeting** in Paris.
14-16 February 2019
- **1st EBMT GvHD Summit.** 16-18 May 2019
- **2nd European CAR T Cell Meeting** in Sitges.
30 January 2020
- **3rd European CAR T Cell Meeting, Virtual.**
4-6 February 2021
- In 2020, other successful mid-sized events, all virtual, were organised such as the **Midterm Focus Meeting on Non-Malignant Diseases;** the **5th International Transplant Course** – and the many Working Parties Scientific and Educational Meetings.
- **EBMT Summit on COVID-19. Virtual.**
29 June - July 01, 2021
- Joint **Basic and Translational Scientific Retreat** with ASTCT in Vail/Colorado
25-27 May 2022

Attendance to EBMT Educational Events



EBMT **e-learning** allows for members to further their education when they want and where they want

- The process for developing an e-learning platform to further educate the EBMT community has started in 2018.
- In 2020, the EBMT launched the e-learning. The pandemic proved to swiftly propel the activities of the e-learning unit, with plentiful COVID-19 webinars in April/May, followed by an increased demand for all types of online learning. Now the e-learning department has a multitude of resources which are available for free to all EBMT Members, such as webinars, e-courses, forums, exams and more.




Welcome to the
EBMT E-learning
Platform



Educational Resources

- The **EBMT Handbook** Hematopoietic Stem Cell Transplantation and Cellular Therapies was released in a new format in January 2019. The project started in 2017 and was coordinated by Enric Carreras, one of the editors together with Carlo Dufour, Mohamad Mohty and Nicolaus Kröger.
- The process of **The EBMT/EHA CAR-T Cell Handbook** started in 2021 in collaboration between EBMT and EHA. This first open access European CAR-T Handbook was coordinated by Isabel Sanchez-Ortega and Francesco Cerisoli and launched during the EBMT-EHA 4th European CAR-T Cell Meeting in February 2022.



The **EBMT Exam**, personal qualification for physicians to assess their knowledge on the clinical aspects of HSCT and Cellular Therapies.


- The 1st edition of the EBMT Exam took place during the first day of the Annual Meeting 2021. 76 registered participants connected online via the EBMT e-learning platform. Participants answered 100 multiple choice questions based on the content of the EBMT Handbook, along with the specific resources pertaining to CAR T cells.





Advocacy & Quality of Care

Nurses Group

- Release of the ground breaking EBMT **Textbook for Nurses** (2018) and the book was transformed into an e-learning programme (2020).
- For the first time, the Nurses Group organised a whole day at the EBMT **International Transplant Course** (6-8 September 2019)
- In 2020, the EBMT Nurses Group produced 2 webinars, one looking at the psychological impact of COVID-19 on nurses and the other on palliative care guidance for patients with severe COVID-19.
- Launch of the JAZZ VOD eLearning (2021)




JACIE Accreditation



JACIE Accreditation


2020 and 2021 continued to see severe negative impact of the pandemic on activities although this has been somewhat mitigated by the introduction of a **remote inspection format** and a so-called **Short Process** which avoid the need for inspectors to travel.



JACIE Accreditation (JACIE Guide)

- JACIE released the **Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy – The JACIE Guide** in March 2021.

This open access book provides a concise yet comprehensive overview on how to build a quality management program for hematopoietic stem cell transplantation (HSCT) and cellular therapy.



JACIE Accreditation

STANDARDS

- Publication of the **7th edition of the FACT-JACIE Standards**. This edition featured Immune Effector Cells, first developed in edition 6.1. These particular standards have sparked a lot of interest given the recent upsurge in CAR-T cellular therapy activity (1 March 2018).
- The process to prepare the **8th edition of the FACT-JACIE Standards** kicked-off in mid-2019 and continued throughout 2020. The first draft was opened for public consultation in April 2020. The 8th edition of the FACT-JACIE Standards was published in May 2021.

BENCHMARKING

- The first phase of the **benchmarking** was launched (October 2020) whereby reports of data-completeness were provided to 416 qualifying centres for the period 2013-2016. Benchmarking has become an annual exercise.
- A total of 395 centres were eligible to participate in the 2021 **benchmarking** exercise.

AND MORE

- In 2018, nine centres in England achieved accreditation for **immune effector cell administration (IEC)** in conjunction with NHS England as part of their CAR-T cell therapy roll-out strategy.
- The **1st joint JACIE-FACT inspection in Latin America** was performed in November 2018 in Córdoba, Argentina.

GoCART Coalition, collaborating to maximise the potential of cellular therapies manufactured from cells and tissues of hematopoietic origin

- Launch of the **GoCART Coalition**: In November 2020, the EBMT and EHA announced a strategic partnership to empower Europe to become a global leader in the cellular therapy field for haematological diseases.
- In 2021, the GoCART Coalition made significant advances in the different work packages: Standards of Care; Data Harmonisation; Education; Scientific Excellence.





Other

New website New logo & name Refocused mission, vision and core values

- During the 44th Annual Meeting, the **EBMT** launched its new and refreshed Website (12 March 2018).
- During the 46th Annual Meeting, the EBMT presented its **new logo and name** as well as the refocused **mission, vision and core values**—which better represent worldwide involvement and modernity (August 2020).




Launch of new EBMT Committees

- The **Patient, Family and Donor Committee** to promote patient advocacy groups for stem cell transplantation and cellular therapies around the globe (2018).
- The **EBMT Patient Engagement Taskforce** to promote active, collaborative participation of patients, donors, caregivers and health care professionals as partners in the society's activities (2020).

Launch of new EBMT Committees

- EBMT created the so-called '**Equality, Diversity and Inclusion**' (**EDI**) **working group** to address our society's gender imbalance at senior levels as well as to promote broader equality, diversity and inclusion issues, and ultimately aiming to improve the inclusion of people across gender, ethnicity, geography, and social categories (2020).
The EBMT Board approved the creation of the **EBMT ED&I Committee** (June 2021).
EDI outcomes are now reported annually to the EBMT Board.
- The **EBMT Trainee Committee**, focused on seeking out the specific needs of trainees working in the field of stem cell transplantation and cellular therapy and providing resources to trainees to become the next generation of leaders (2021).



EBMT Office in Shanghai

- After an initiative from the Global Committee, chaired by Prof. Gorin, the EBMT officially opened a satellite foundation **office in Shanghai**, China (15 December 2020). with the objective to promote convenient and in-depth exchange between the Chinese haematology community Chinese nurses and the EBMT, strengthen multi-centre clinical innovation and cooperation, share scientific experience, standards and protocols, and ultimately provide the best treatment and care for patients.



Thanks to the current and past Executive Committee Members and Medical Director





Thanks to EBMT

“Working and serving the EBMT either as a member of its Working Parties and Committees or, more recently, in a leadership position has been a huge honour and privilege and has given me a profound sense of professional fulfilment”.



Treasurer's Annual Financial Report for 2021

Harry Dolstra, EBMT Treasurer

Final 2021 numbers for voting

Financial highlights

Source of Income

	2021	
	EUR	%
EBMT Members donations	603.000	6,0%
Scientific Sponsors donations	575.000	5,7%
Annual Meeting	3.962.000	39,5%
Results from investments	1.000	0,0%
Non-earmarked Income	5.141.000	51,3%
Grants for Studies, Clinical Trials & Education	4.623.000	46,1%
Accreditation (JACIE)	257.000	2,6%
Earmarked Income	4.880.000	48,7%
Total Income	10.021.000	100,0%

Destination of resources

	2021	
	EUR	%
Scientific Studies	3.400.000	42,4%
EBMT Registry	610.000	7,6%
Annual Meeting	579.000	7,2%
Educational Activities	1.283.000	16,0%
Standards & Accreditation (JACIE)	558.000	7,0%
Total Mission Cost	6.430.000	80,2%
Management and Administration	1.583.000	19,8%
Total Expenditure	8.013.000	100,0%

Position of EBMT - rating

Program %	Cost to Raise \$100	Efficiency Rating
90-100%	\$0 - 4	A+
80 - 89%	\$5 - 11	A
75 - 79%	\$12 - 15	A-
72 - 74%	\$16 - 19	B+
68 - 71%	\$20 - 26	B
65 - 67%	\$27 - 30	B-
61 - 64%	\$31 - 33	C+
56 - 60%	\$34 - 37	C
50 - 55%	\$38 - 40	C-
36 - 49%	\$41 - 59	D
0 - 35%	\$60 - 100	F

Current position EBMT

Final 2021 numbers for voting

Financial outcome

Total Income

Total Costs

Gross Result

Earmarked

Net result

2021	
EUR	%
10.021.000	100,0%
8.013.000	80,0%
2.008.000	20,0%
409.000	4,1%
1.599.000	15,9%

Final Conclusions

The ongoing positive financial development of the organization over the past years has allowed EBMT to further build on its strategic goals and improve its organizational structure.

Current highlights include the successful virtual meetings during the COVID-19 pandemic, increasing E-learning opportunities, registry upgrade, cellular therapy registry, benchmarking system, CAR T PASS studies, staff compensation and human resource management, information technology innovation, COVID-19 studies and the Science fund.


In spite of the financial challenges related to the ongoing COVID-19 pandemic, EBMT will be closing the year 2021 with a positive total result of 2,008 k€ (expenses of 8,013 k€ and a total income of 10,021 k€) thanks to the fantastic work of the EBMT staff, community and the use of our financial reserves.

Covid-19

Due to the continuing issues regarding the Covid-19 virus the EBMT has virtualized most of its events.

Income and human resources evolution

EBMT FTE evolution



Evolution Income and Staff costs



Spending our financial resources on our missions

Our steady annual income has been used to strengthen our growing organisation as a whole.

For 2021, the budget needed for management and administration (i.e., Board and Executive Office expenses) stabilized to 19.8% which allocates 80.2% to our scientific studies, registry, accreditation and education like the 2021 Annual Meeting, E-learning and educational events.

Therefore, EBMT remains a very efficient organisation when assessed by international rankings (“A” according to CharityWatch).



Continue with a well-balanced strategic financial roadmap

In 2021, we continued to secure and improve our staff positions while further optimizing EBMT organizations through a well-balanced financial roadmap for the future of EBMT. Our goal was to be able to cover all financial challenges in line with our ambitions but also provide a strong backbone for the organization.

The EBMT Board decided to partially release allocated reserves in 2021 (409,000€) to support our organization for the next few years which covers the following topics and areas.



1) Continue with our virtual meetings

Due to the ongoing COVID-19 pandemic we organised for the second time our annual congress as a virtual meeting while vaccination campaigns were ongoing. Thanks to the great work and dedication of the Barcelona office, the 2021 virtual annual meeting was a great success because we were able to maintain the high level of education, the support of our sponsors and the engagement of our delegates. The completed in-housing operations of successive EBMT educational events strengthens the EBMT's educational positioning and visibility within the virtual arena and by having financial control.



2) Adapting the organizational structure

In 2021, we further adapted the managerial infrastructure of the EBMT which is structured in six departments Registry, Clinical Research, Education & Events, Advocacy & Quality of Care, Sales & Development and Support. Each department is led by a department Director who, together with the Executive Director and Medical Officer, form the EBMT Management Team.

In 2021 we continued with improving the Clinical Research, Sales and Support departments in order to increase and streamline the process of setting up membership, sponsorship, retrospective and prospective studies in collaboration with pharma, institutions and non-profit organisations as well as marketing & communications. The sponsorships and funded studies are a growing segment of the activities of EBMT and important financial pillar for our strategic mission. Due to the solid financial situation of EBMT, we were able to sustain all staff positions during the ongoing COVID-19 pandemic and finance the new, key positions within the transformed EBMT organisational structure. Further streamlining and restructuring of the organigram will continue in 2022 in order to increase the efficiency of EBMT.



3) COVID Task force and science fund

A COVID task force within EBMT was formed to support patients and the EBMT community during the COVID-19 pandemic. All working parties were involved in the COVID task force which was very productive in developing general and vaccination guidelines for patients, donors and the EBMT community, scientific surveys and Covid-19 related scientific studies. The EBMT Board decided to strategically allocate reserves in a science fund to support the Covid-19 studies and for strategic scientific studies in next years. In education and events contract management a Covid-19 clause was incorporated to minimize the inherited financial risk.



4) Continuing the CAR T PASS studies

After receiving the qualification opinion from EMA regarding the cellular therapy module of the EBMT Registry, the Board decided to raise manpower to support this initiative, which will collect post-market evidence for safety and efficacy of different commercial CAR T products. Contracts with three big pharma companies have been signed and more companies are likely to follow. The finance support behind these contracts allows for more human resources to execute these PASS studies and increase the Registry data and data quality. This registry tool will be helpful for all researchers executing clinical studies with immune effector cells to gather more comprehensive data sets.



5) Updating the EBMT REGISTRY

In 2021, we kept working on building the future Registry into a new IT system while continuing to enter transplant and cellular therapy data in ProMISe. Furthermore, we built a new CASTOR database to enter CAR T data for the EBMT and PASS scientific studies. Building of the future Registry platform has the highest financial priority. Reserves have been earmarked to cover all expected costs. In addition, reserves are being used and held for any unexpected expenses. Furthermore, the London, Leiden and Paris offices were and are still closely working together on this project under the supervision of the Registry Director, and the new Deputy Executive Director for the Registry upgrade.



6) JACIE remote inspections

In 2021, JACIE deployed a system for remote inspections and as an optional format for re-accreditations including IEC inspection. Remote inspections have made it possible to carry out inspections that would have had to be cancelled due to the risk of contagion. In addition, JACIE has also implemented a hybrid inspection model with part of the inspection team onsite and others by remote inspection. Following the forced stop to activity due to the Covid-19 pandemic, JACIE was pleased to resume on-site inspections during the last quarter of 2021. Further streamlining and restructuring formats will continue in 2022 in order to increase the efficiency of JACIE accreditation.



AUDITING PROCESS



At the time of preparation of this presentation (4 March 2022), the audit process had not yet been completed.

No information from the auditors has reached us that indicates we won't obtain an "unqualified opinion".

Throughout the last years EBMT obtained unqualified opinions, which demonstrates that the EBMT is maintaining its high standard of modern management, improving its financial stability and provides assurance that money is spent and allocated according to our mission.

At the end of the audit process EBMT will receive an Auditor's Management Letter. The outcome of this will be presented during one of the next Board meetings.



Andreu Gusi



Bas Natkiel



Liesbeth Hoekstra



Erwin Timmers

THANKS TO:

**Financial committee members
from 2019 and update ToR
4 year mandate**



Harry Schouten



Alejandro Madrigal

Thanks!






EBMT Secretary's Annual Activity & Membership Report for 2021

48th Annual Meeting of the EBMT

John Snowden, EBMT Secretary

Membership Overview

EBMT Members



Source: Promise January 2022

Centre members

CENTRES Membership Overview

Global Figures

	GAM 2022	GAM 2021
Number of EBMT CENTRES	620	579
Of which PROVISIONAL centres	35	9
Of which have been REACTIVATED	17	4
Of which FULL centres	534	512
Of which ASSOCIATE centres	51	58

Source: Promise January 2022

CENTRES Membership Overview

Global Figures

1	Germany	90	89
2	Italy	85	79
3	France	58	48
4	UK	53	51
5	Spain	48	47
6	Turkey	38	39
7	China	22	4
8	Poland	21	17
9	Belgium	15	15
10	Netherlands	15	15

The **620** EBMT centres are located in **55** countries

The **top 10** split of Centres represents **445** Centres (71% of total)

CENTRES Membership Overview

New centres

CIC	Institution	Country
488	Sozialstiftung Bamberg	Germany
489	linikum Hochsauerlnad Department	Germany
499	Instituto de Prevision Social	Paraguay
891	Hematology Center R.H Yeolyan	Armenia
892	Carl-Thiem Clinic	Germany
893	N.N. Blokhin National Medical Research Center of Oncology, Research Institute of Pediatric Oncology and Hematology	Russia
895	Staetisches Krankenhaus Kiel	Germany
899	National Institute of Blood Diseases & Bone Marrow Transplantation	Pakistan
998	Instituto de Cancerologia S.A	Colombia
999	Groupe Hospitalier Artois-Ternois	France
1007	Marmara University	Turkey
1008	Institute of Hematology, Chinese Academy of Medical Sciences	China
1009	Bucharest University Emergency Hospital	Romania
1011	INSTITUTUL REGIONAL DE ONCOLOGIE	Romania
1012	Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine	China
1013	Central South University,Xiangya Hospital	China
1014	Wuhan Union Hospital	China
1015	Shenzhen Children`s Hospital	China
1016	The First Affiliated Hospital of Xi'an Jiaotong University	China

CENTRES Membership Overview

New centres

CIC	Institution	Country
1017	Xinqiao Hospital of Army Medical University	China
1018	Tongji Hospital Affiliated to Tongji University	China
1019	Morozov Children's Hospital	Russia
1020	"METAXA" CANCER HOSPITAL	Greece
1021	Center of Oncology of the Lublin Region St. Jana z Dukli	Poland
1023	First Affiliated Hospital of Sun Yat-sen University	China
1024	Lanzhou University Second Hospital	China
1025	First affiliated hospital of Xinjiang Medical University	China
1026	The Second Affiliated Hospital of Xi'an Jiaotong University	China
1027	First Affiliated Hospital of Zhengzhou University	China
1028	920th Hospital of Joint Logistics Support Force	China
1029	Beijing friendship Hospital, Capital Medical University	China
1030	The First Affiliated Hospital of Wenzhou Medical University	China
1031	Nanfang Hospital, Southern Medical University	China
1032	First Affiliated Hospital of Zhejiang Chinese Medical University	China
1033	University Hospital Split	Croatia

Individual Members

Individual Membership Overview

Global Figures

	GAM 2022	GAM 2021
Number of INDIVIDUAL members	163	144
<i>Of which PROVISIONAL individuals</i>	44	38
<i>Physicians</i>	146	100
<i>Nurses</i>	38	38
<i>Other</i>	12	3
<i>Patient Representative</i>	3	2
Honorary members	36	30

Source: Promise January 2022

Individual Membership Overview

New individuals

The following 38 Provisional Individual Members await your approval

CIC	Full name	Role	Country
10194	Radhakrishnan vivek Sulekha	Physician	India
10195	Lucia Prezioso	Physician	Italy
10196	Mohamad Azzam Ziade	Physician	UEA
10197	Cristian Sotomayor	Physician	Chile
10198	Claudia Boglione	Nurse	Italy
10199	Christopher Dheepa	Physician	Singapore
10235	Denis Fedorenko	Physician	Russia
10236	Abdulhamid Bazarbachi	Physician	USA
10237	Rama Al Hamed	Physician	USA
10238	Ahmed Omari	Nurse	Saudi Arabia
10239	Amira Fayad	Physician	Egypt
10240	Antonio Jimenez	Physician	USA
10241	Ernesto Ayala	Physician	USA
10243	Rasha Alyoussef	Physician	Syria
10244	Deepak Chellapandian	Physician	Russia
10245	Theres Lange	Pharmacist	Germany
10246	Pier Edoardo Rovatti	Physician	Italy
10247	Helen Gillespie	Nurse	UK
10248	Amira Fayad	Physician	Egypt
10249	Marcel van den Brink	Physician	USA
10250	Sanjeev	Physician	India
10251	Tanseem Ganijee	Pharmacist	UK

Individual Membership Overview

New individuals

CIC	Full name	Role	Country
10252	Cristina Toffalori	Scientist	Italy
10253	Christian Reinhardt	Physician	Germany
10254	Sherif Badawy	Physician	USA
10255	Sergio Giralt	Physician	USA
10327	Aditya Kumar Gupta	Physician	India
10419	Najla El Jurdi	Physician	USA
10840	Alim Janhavi	Nurse	India
10869	Boaz Spermon	Patient Advocate	
10877	Sylvia Dulan	Nurse	USA
10878	Arijit Bishnu	Physician	India
10879	Anil Sharma	Physician	India
10880	Faheema Hasan	Physician	India
10881	Akshay Lahoti	Student	India
10882	Sagar Bhattad	Physician	India
10883	Sara Makkeyah	Physician	Egypt
10884	Francisco Barriga	Physician	Chile
10887	Yadanar Lwin	Physician	UK
10888	Carmem Bonfim	Physician	Brazil
10889	Andreza Alice Ribeiro	Physician	Brazil
10890	Jagath Ranasinghe	Physician	Sri Lanka
10891	Madiha Iqbal	Physician	USA
10900	Aleksandr Lazaryan	Physician	USA

Full Centre Membership to Associate

Full Centre Membership to Associate

54 full member centres have been unable to report all data in 2021.

Normally, these centres would be downgraded to associate membership, however, due to the COVID pandemic we understand that many centres have been unable to prioritise this activity. Downgrading will therefore be postponed until 2023 in order to provide sufficient time for centres to catch up with all reported data.

In Memoriam

**A moment of silence to
remember colleagues that
have sadly left us in 2022**



Dr Maria Gilleece



Prof Amit Patel



Dr Jean-Michel Boiron

Thanks!





EBMT ELECTION RESULTS



All eligible to vote Principal Investigators (525) from EBMT full membership centres were invited to vote online for the nominated, endorsed and approved WP Chair candidates for 2022.

Voting took place online from Wednesday 9th March, 10h00 CET until Monday 21st March, 20h00 CET

196 ballots submitted of 525 eligible voters = 37% participation.



EBMT Acute Leukaemia Working Party Chair - Fabio Ciceri

EBMT Acute Leukaemia Working Party Chair - Fabio Ciceri PLURALITY

Yes - I approve the candidate

187 votes (99.5%)

No - I reject the candidate

1 vote (0.5%)

Yes - I approve the candidate wins with 99.5% of the vote.

188 votes tallied and 8 abstentions



Congratulations to **Fabio Ciceri**
EBMT Acute Leukaemia Working Party Chair



EBMT Chronic Malignancies Working Party Chair - Donal McLornan

EBMT Chronic Malignancies Working Party Chair - Donal McLornan PLURALITY

Yes - I approve the candidate

171 votes (97.7%)

No - I reject the candidate

4 votes (2.3%)

Yes - I approve the candidate wins with 97.7% of the vote.

175 votes tallied and 21 abstentions



Congratulations to Donal McLornan
EBMT Chronic Malignancies Working Party Chair



EBMT Cellular Therapy & Immunobiology Working Party Chair

EBMT Cellular Therapy & Immunobiology Working Party Chair PLURALITY

Annalisa Ruggeri

140 votes (74.1%)

Jurgen Kuball

49 votes (25.9%)

Annalisa Ruggeri wins with 74.1% of the vote.

189 votes tallied and 7 abstentions



Congratulations to Annalisa Ruggeri
EBMT Cellular Therapy & Immunobiology Working
Party Chair



In addition to voting for the 2022 WP Chair candidates, all eligible to vote Pls, were also invited to approve the following:

- **EBMT President's Activity Report for 2018-2021**
- **EBMT Treasurer's Financial Report for 2021**
- **EBMT Secretary's Membership Report for 2021**
- **EBMT Bylaw Amendment Approval of Article 14, 16 and 18**



EBMT President's Activity Report 2018-2021

EBMT President's Activity Report 2018-2021 PLURALITY

Yes - I approve the President's Activity Report 2018-2021

184 votes (98.4%)

No - I reject the President's Activity Report 2018-2021

3 votes (1.6%)

Yes - I approve the President's Activity Report 2018-2021 wins with 98.4% of the vote.

187 votes tallied and 9 abstentions



EBMT Treasurer's Annual Report for 2021

EBMT Treasurer's Annual Report for 2021 PLURALITY

Yes - I approve the Treasurer's Annual Report for 2021

184 votes (100.0%)

No - I reject the Treasurer's Annual Report for 2021

0 votes (0%)

Yes - I approve the Treasurer's Annual Report for 2021 wins with 100.0% of the vote.

184 votes tallied and 12 abstentions



EBMT Secretary's Annual Report for 2021

EBMT Secretary's Annual Report for 2021 PLURALITY

Yes - I approve the Secretary's Annual Report for 2021

183 votes (99.5%)

No - I reject the Secretary's Annual Report for 2021

1 vote (0.5%)

Yes - I approve the Secretary's Annual Report for 2021 wins with 99.5% of the vote.

184 votes tallied and 12 abstentions



Bylaw Amendment Approval of Article 14, 16 and 18

Bylaw Amendment Approval of Article 14, 16 and 18 PLURALITY

Yes - I approve the amendments

178 votes (97.8%)

No - I reject the amendments

4 votes (2.2%)

Yes - I approve the amendments wins with 97.8% of the vote.

182 votes tallied and 14 abstentions



EBMT OUTGOING BOARD MEMBERS

We would like to take this opportunity to thank the following outgoing board members for their support and commitment to the Scientific Council and Board of Association during their mandate.



Nicolaus Kröger

EBMT President 2017 - 2022



Christian Chabannon

Cellular Therapy & Immunobiology Working Party Chair 2018 – 2022

Scientific Council Co-Chair 2018 – 2020

Scientific Council Representative with the Registry Portfolio 2020 – 2022



Mohamad Mohty

Acute Leukaemia Working Party Chair 2018 – 2022

Scientific Council Chair 2018 – 2020

Scientific Council Representative with the Education Portfolio 2020 – 2022



Ibrahim Yakoub-Agha

Chronic Malignancies Working Party Chair 2018 – 2022



Bregje Verhoeven

Patient Advocacy Committee Chair 2018 – 2022

Thanks!

